Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
- Read more about Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
Suzanne E. Mahady, Germaine Wong, Jonathan C. Craig, Jacob George – 18 June 2012 – Nonalcoholic steatohepatitis (NASH) is the commonest liver disease in developed countries. However, there are no current data on the cost‐effectiveness of therapeutic options such as lifestyle modification, pioglitazone, or vitamin E. We undertook a cost utility analysis to compare these strategies.